{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nzljm1\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nzljm1\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;15\\\/12\\\/22\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;15\\\/12\\\/22\u0022}],\u0022ac\u0022:{\u0022spmdc;15\\\/12\\\/22\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;15\\\/12\\\/22\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/advagg_css\/css__ce2QY63WIanKyr8eSq7eavr1XQRRmFD6ZSmwpyJi8lM__zXwFqpqmxrZOXXcd_TpBQpjuELbmIP9wBR5UuTDWAO4__YJWWMMdfCJuAFm5cUEp88OsodhO3ZA-2lzRfoBsSlk4.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\u003Cp id=\u0022p-1\u0022\u003EAtrial fibrillation can become self-sustaining due to structural remodeling that results in changes in ion currents over time. Treatment of atrial fibrillation with ablation does not appear to be improved by additional substrate ablation (CFE or Lines) when performed in addition to PVI. There is also mounting evidence for the role of rotors in AF. Many patients experience termination of atrial fibrillation following ablation of rotor sites, suggesting that therapies that target rotors may be one approach to reduce the burden of AF.\u003C\/p\u003E\u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003Eatrial fibrillation\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ECFE\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Ecomplex fractionated electrogram ablation\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eeplerenone\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EFIRM\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Efocal impulse and rotor modulation\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Epulmonary vein isolation\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EPVI\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Erotor\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ESTAR AF II\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Ecardiology \u0026amp; cardiovascular medicine clinical trials\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Einterventional techniques \u0026amp; devices\u003C\/li\u003E\u003C\/ul\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\u003Cp id=\u0022p-2\u0022\u003EAtrial fibrillation (AF) is the most common atrial arrhythmia and a strong independent risk factor for stroke, heart failure, and death. Catheter ablation is an established treatment to achieve and maintain sinus rhythm in patients with recurrent AF. However, persistent AF is resistant to ablation and medical therapy, creating an unmet medical need in treatment of this disorder.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-2\u0022\u003E\u003Ch2 class=\u0022\u0022\u003ESelf-sustaining Persistent Atrial Fibrillation\u003C\/h2\u003E\u003Cp id=\u0022p-3\u0022\u003EStanley Nattel, MD, Montreal Heart Institute, Montreal, Quebec, Canada, presented an overview of longstanding persistent AF.\u003C\/p\u003E\u003Cp id=\u0022p-4\u0022\u003EAF becomes self-sustaining and perpetuates itself in the short term by causing ion current changes and action potential duration shortening that promotes reentrant arrhythmias. However, this factor alone is not sufficient to cause longstanding persistent AF. Structural remodeling is also essential for the development of this disorder, and tissue fibrosis is a major component of the process [Martins RP et al. \u003Cem\u003ECirculation\u003C\/em\u003E. 2014]. There is a progressive increase in atrial fibrosis as AF becomes increasingly persistent. Fibrosis, particularly in epicardium, separates myocytes and creates conduction barriers [Verheule S et al. \u003Cem\u003ECirc Arrhythm Electrophysiol\u003C\/em\u003E. 2010].\u003C\/p\u003E\u003Cp id=\u0022p-5\u0022\u003EWhile the changes in the electrical component are reversible after AF termination, the structural changes reverse slowly and in some patients do not occur at all [Haissaguerre M et al. \u003Cem\u003ECirculation\u003C\/em\u003E. 2014]. Such tissue remodeling can accumulate over time, leading to longstanding AF. However, other factors such as cardiovascular disease and normal aging can also cause structural changes that promote AF.\u003C\/p\u003E\u003Cp id=\u0022p-6\u0022\u003EElucidation of the mechanism of AF development led to some clinical attempts to target upstream factors in order to prevent the progression of fibrosis in patients with longstanding persistent AF.\u003C\/p\u003E\u003Cp id=\u0022p-7\u0022\u003EA study by Ito and colleagues [\u003Cem\u003EAm J Cardiol\u003C\/em\u003E. 2013] evaluated the effects of eplerenone, a selective aldosterone blocker, on clinical outcomes after radiofrequency catheter ablation in patients with longstanding persistent AF (n\u2005=\u2005161). After 24 months of follow-up, the rate of freedom from AF recurrence was significantly higher in the eplerenone group than in the control group (60% vs 40%, respectively; \u003Cem\u003EP\u003C\/em\u003E\u2005=\u2005.011; \u003Ca id=\u0022xref-fig-1-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv id=\u0022F1\u0022 class=\u0022fig pos-float  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/12\/22\/F1.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Atrial Fibrillation\u0026#x2013;Free Survival by TreatmentKaplan-Meier curves showing the rate of freedom from AF recurrence in the eplerenone and noneplerenone groups during 24-month follow-up.Reprinted from Am J Cardiol, Vol. 111, Ito Y et al, Effect of Eplerenone on Maintenance of Sinus Rhythm After Catheter Ablation in Patients With Long-Standing Persistent Atrial Fibrillation, Pages No. 1012-1018, Copyright (2013), with permission from Elsevier.\u0022 class=\u0022fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-2107908646\u0022 data-figure-caption=\u0022\u0026amp;lt;div xmlns=\u0026amp;quot;http:\/\/www.w3.org\/1999\/xhtml\u0026amp;quot;\u0026amp;gt;Atrial Fibrillation\u0026#x2013;Free Survival by TreatmentKaplan-Meier curves showing the rate of freedom from AF recurrence in the eplerenone and noneplerenone groups during 24-month follow-up.Reprinted from \u0026amp;lt;em\u0026amp;gt;Am J Cardiol\u0026amp;lt;\/em\u0026amp;gt;, Vol. 111, Ito Y et al, Effect of Eplerenone on Maintenance of Sinus Rhythm After Catheter Ablation in Patients With Long-Standing Persistent Atrial Fibrillation, Pages No. 1012-1018, Copyright (2013), with permission from Elsevier.\u0026amp;lt;\/div\u0026amp;gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cimg class=\u0022fragment-image\u0022 alt=\u0022Figure 1.\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/12\/22\/F1.medium.gif\u0022\/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/12\/22\/F1.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 1.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/12\/22\/F1.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/16711\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 1.\u003C\/span\u003E \u003Cp id=\u0022p-8\u0022 class=\u0022first-child\u0022\u003EAtrial Fibrillation\u2013Free Survival by Treatment\u003C\/p\u003E\u003Cp id=\u0022p-9\u0022\u003EKaplan-Meier curves showing the rate of freedom from AF recurrence in the eplerenone and noneplerenone groups during 24-month follow-up.\u003C\/p\u003E\u003Cp id=\u0022p-10\u0022\u003EReprinted from \u003Cem\u003EAm J Cardiol\u003C\/em\u003E, Vol. 111, Ito Y et al, Effect of Eplerenone on Maintenance of Sinus Rhythm After Catheter Ablation in Patients With Long-Standing Persistent Atrial Fibrillation, Pages No. 1012-1018, Copyright (2013), with permission from Elsevier.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-11\u0022\u003EOther studies have attempted to address AF risk factors in hopes that such interventions would reduce the prevalence of AF and alleviate AF burden. In a partially blinded, randomized controlled study by Abed and colleagues [\u003Cem\u003EJAMA\u003C\/em\u003E. 2013], 150 patients were randomized to either weight management (intervention) or general lifestyle advice (control). Weight reduction resulted in reduced AF symptom burden and severity and in beneficial cardiac remodeling after a 15-month follow-up. Managing obstructive sleep apnea, another risk factor for AF, was associated with a lower recurrence of AF in a prospective study that included 153 patients who underwent extensive encircling pulmonary vein isolation (PVI) for drug-refractory AF [Naruse Y et al. \u003Cem\u003EHeart Rhythm\u003C\/em\u003E. 2013].\u003C\/p\u003E\u003Cp id=\u0022p-12\u0022\u003EDr Nattel concluded that strategies to improve outcomes include earlier and more effective interventions, aggressive risk factor management, and potential therapies that prevent substrate progression.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-3\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EAblation of Persistent Atrial Fibrillation\u003C\/h2\u003E\u003Cp id=\u0022p-13\u0022\u003EAblation of AF is challenging and usually less successful for persistent AF than for paroxysmal AF. The European Heart Rhythm Association\/Heart Rhythm Society guidelines on cardiac resynchronization therapy in heart failure suggest that more extensive ablation should be considered [Daubert JC et al. \u003Cem\u003EHeart Rhythm\u003C\/em\u003E. 2012]; however, it remained unclear whether more extensive ablation improves outcomes.\u003C\/p\u003E\u003Cp id=\u0022p-14\u0022\u003EAtul Verma, MD, Southlake Regional Health Center, Newmarket, Ontario, Canada, presented results of the STAR AF II trial [Verma A et al. \u003Cem\u003EN Engl J Med\u003C\/em\u003E. 2015], demonstrating that there was no reduction in the rate of recurrent AF with either linear ablation (Lines) or ablation of complex fractionated electrograms (CFEs) performed at the time of PVI in patients with persistent AF.\u003C\/p\u003E\u003Cp id=\u0022p-15\u0022\u003ESTAR AF II was a multicenter, prospective, randomized trial with the objective to compare the efficacy of 3 different catheter ablation strategies in patients with persistent AF: PVI alone vs PVI plus CFE vs PVI plus Lines. The primary end point was freedom from documented AF lasting \u0026gt;\u200530 seconds at 18 months after 1 or 2 ablation procedures with or without antiarrhythmic medications.\u003C\/p\u003E\u003Cp id=\u0022p-16\u0022\u003EA total of 589 patients were randomized 1:4:4 to PVI, PVI plus CFE, and PVI plus Lines, respectively. Successful PVI was performed in 97% of patients across all groups, CFEs were eliminated in 80%, and bidirectional block across both roof and mitral lines was achieved in 74%.\u003C\/p\u003E\u003Cp id=\u0022p-17\u0022\u003EAfter 18 months, 59% of patients assigned to PVI alone were free from recurrent AF compared to 49% of patients assigned to PVI plus CFE and 46% of patients assigned to PVI plus Lines (\u003Cem\u003EP\u003C\/em\u003E\u2005=\u2005.15). There were no significant differences between the groups in regard to the secondary end points, including freedom from AF after 2 ablation procedures and freedom from any atrial arrhythmia. AF burden was reduced significantly in all treatment groups. Complications were rare and did not differ significantly between the groups.\u003C\/p\u003E\u003Cp id=\u0022p-18\u0022\u003EDr Verma concluded that in the largest randomized trial to date evaluating the methods of AF ablation, there was no reduction in AF when additional substrate ablation (CFE or Lines) was performed in addition to PVI. Novel targets for ablation may include rotors, repetitive patterns, and non-PVI foci.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-4\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EThe Role of Rotors in Atrial Fibrillation\u003C\/h2\u003E\u003Cp id=\u0022p-19\u0022\u003EOmer Berenfeld, PhD, University of Michigan Health System, Ann Arbor, Michigan, USA, and Michel Ha\u00efssaguerre, MD, University of Bordeaux, Talence, France, discussed rotors and their role in AF mechanisms and treatment.\u003C\/p\u003E\u003Cp id=\u0022p-20\u0022\u003ERotors are a special type of reentrant circuits of action potentials possibly revolving around a normally excitable core; in contrast with the reentries in which the wavefront and wavetail do not meet, the curved front and tail of the rotor meet each other near their pivoting tip. Rotors are difficult to study, mainly because of the low voltage amplitude at their core and their tendency to meander and drift, prompting phase and frequency domain algorithms for their mapping [Rodrigo M et al. \u003Cem\u003EHeart Rhythm\u003C\/em\u003E. 2014].\u003C\/p\u003E\u003Cp id=\u0022p-21\u0022\u003EVarious mapping methods have been developed to detect and map rotor activity in humans. A more invasive method involves the use of a basket catheter [Narayan SM et al. \u003Cem\u003EJ Am Coll Cardiol\u003C\/em\u003E. 2012]. The catheter provides localized atrial mapping but does not capture all tissue surface. Body surface mapping and electrocardiographic imaging are less invasive and provide panoramic biatrial mapping, but do not capture smaller signals [Rodrigo M et al. \u003Cem\u003EHeart Rhythm\u003C\/em\u003E. 2014].\u003C\/p\u003E\u003Cp id=\u0022p-22\u0022\u003EA mechanistic role of rotors in AF is suggested by termination and freedom from AF following the ablation of rotor sites. Treatment of AF in the CONFIRM trial [Narayan SM et al. \u003Cem\u003EJ Am Coll Cardiol\u003C\/em\u003E. 2012] (n\u2005=\u200592) resulted in AF termination or consistent slowing in 86% of patients who underwent targeted focal impulse and rotor modulation vs 20% of those treated by conventional ablation alone.\u003C\/p\u003E\u003C\/div\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2015 SAGE Publications\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/15\/12\/22.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_figures.js?nzljm1\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nzljm1\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}